MAP2K7 and melanoma: Downregulation of SLC7A11 (cysteine-glutamate antiporter xCT gene), increased cytotoxic ROS levels in drug-resistant melanoma associated with apoptosis, in vivo activity in vemurafenib-resistant A375 melanoma clones, clinical activity in patients with advanced BRAF + MEK inhibitor-resistant melanoma